2019 – 2020 Advisory Committee

Firas El Chaer, MD, is a hematology and medical oncology specialist, and an assistant professor of medicine at the University of Virginia, Emily Couric Clinical Cancer Center.

In addition to infectious diseases in immunocompromised patients with cancer, Dr. El Chaer specializes in hematologic malignancies and stem cell transplantation, and has been working on improving the outcomes for acute leukemias in adults by focusing on targeted therapies and overcoming resistance mechanisms.

Dr. El Chaer completed a dedicated fellowship in infectious diseases—in which he is board certified—at Baylor College of Medicine and MD Anderson Cancer Center joint program. He is a recipient of the Arnold P. Gold Humanism Honor Society Award for role model physician teacher and excellence in clinical care, leadership, compassion, and dedication to service.

Ashkan Emadi, MD, PhD, is a hematologist/medical oncologist, organic chemist, and professor of medicine and pharmacology at the University of Maryland School of Medicine, Marlene & Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

He has been working on changing the outcomes for acute leukemias in adults by designing, conducting, and analyzing rationally-based innovative strategies that will positively affect cures and translate into prolongation of meaningful survival. His in-depth knowledge and experience in organic chemistry and drug design, pre-clinical and clinical development, and drug approval covers the entire spectrum of drug development.

Dr. Emadi developed novel methodologies for the regiospecific synthesis of multiple naphthoquinone derivatives related to the natural product conocurvone, which exhibit HIV integrase inhibitory activity as well as anti-neoplastic activity. His clinical translational research is focused on exploiting and targeting glutamine and glucose metabolic pathways in neoplastic cells. He is the principal investigator of fully funded investigator-initiated clinical trials for the treatment of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) involving tryptophan and glutamine metabolisms.

Dr. Emadi is a recipient of the Martin and Mary Kilpatrick Award for exceptional ability and promise in chemistry and outstanding achievement in chemical research.

Jeffrey Kendall, PsyD, LP, is the Director of Oncology Supportive Care at M Health Fairview in Minneapolis, MN. He joined the University of Minnesota Cancer Care program in 2016 where he is dedicated to addressing the impact of cancer on individuals and families. Currently his professional time is divided among direct patient care, program administration, program development, and research collaboration.

Dr. Kendall speaks nationally and internationally and has published 40 journal articles and abstracts on topics related to psychosocial oncology and cancer survivorship. Dr. Kendall serves on committees for the American Psychosocial Oncology Society and the Association of Community Cancer Centers.

Dr. Kendall received his Doctorate from Indiana State University and completed his Post-Doctoral Fellowship in Psychosocial Oncology at Roswell Park Cancer Institute in Buffalo, New York.

Jeff Klaus, PharmD, BCPS, obtained his Doctorate of Pharmacy from the University of Houston College of Pharmacy and completed two years of pharmacy residency training at Barnes-Jewish Hospital in St. Louis, Missouri. Since completing residency training he has served as a clinical pharmacy specialist at Barnes-Jewish Hospital, and specializes in hematologic malignancies and hematopoietic cell transplantation. He serves as a preceptor for pharmacy residents in the Barnes-Jewish Hospital pharmacy residency programs, for pharmacy students from St. Louis College of Pharmacy and Xavier University of Louisiana College of Pharmacy, and is adjunct faculty at the St. Louis College of Pharmacy, where he has delivered lectures on hematologic malignancies.

In his current role, he divides his time between direct patient care, education of pharmacy students and residents, facilitation of clinical research, and the conduct of retrospective research with a focus on the management of hematologic malignancies and infectious diseases.

Sandra Kurtin, PhD, ANP-C, AOCN, is a hematology/oncology nurse practitioner at the University of Arizona Cancer Center and an assistant professor of clinical medicine and adjunct clinical assistant professor of nursing at the Univrsity of Arizona’s College of Medicine. With over 30 years of experience in advanced practice, her oncology practice focuses on benign and malignant hematological disorders. Her research focuses on health technology engagement, communicative health literacy, and health self-management among older adult cancer survivors, as well as practice transformation to achieve best practice.  

Dr Kurtin is a founding board member and the immediate past president of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. She also serves on the Hematology Board for the American Board of Internal Medicine. In addition to these accolades, she has been an associate editor for The Journal of the Advanced Practitioner in Oncology since its inception and an editorial board member for JCO Clinical Cancer Informatics, ASH News, The Clinical Journal of Oncology Nursing, and the ASCO People Living with Cancer website. She has presented numerous regional, national, and international lectures on oncology-related topics and has published numerous articles in peer-reviewed journals. 

Dr Kurtin earned her BSN and MS in oncology nursing, her post-graduate certification in geriatric and adult practice, and her PhD in nursing at the University of Arizona. She is also an inaugural Fellow of Advanced Practice in Oncology (FAPO).